已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Estimands for overall survival in clinical trials with treatment switching in oncology

医学 临床试验 肿瘤科 指南 内科学 心理学 医学物理学 重症监护医学 病理
作者
Juliane Manitz,Natalia Kan‐Dobrosky,Hannes Buchner,Marie‐Laure Casadebaig,Evgeny Degtyarev,Jyotirmoy Dey,Vincent Haddad,Jie Fei,Emily Martin,Mindy Mo,Kaspar Rufibach,Yue Shentu,Viktoriya Stalbovskaya,Rui Tang,Godwin Yung,Jiangxiu Zhou
出处
期刊:Pharmaceutical Statistics [Wiley]
卷期号:21 (1): 150-162 被引量:13
标识
DOI:10.1002/pst.2158
摘要

An addendum of the ICH E9 guideline on Statistical Principles for Clinical Trials was released in November 2019 introducing the estimand framework. This new framework aims to align trial objectives and statistical analyses by requiring a precise definition of the inferential quantity of interest, that is, the estimand. This definition explicitly accounts for intercurrent events, such as switching to new anticancer therapies for the analysis of overall survival (OS), the gold standard in oncology. Traditionally, OS in confirmatory studies is analyzed using the intention-to-treat (ITT) approach comparing treatment groups as they were initially randomized regardless of whether treatment switching occurred and regardless of any subsequent therapy (treatment-policy strategy). Regulatory authorities and other stakeholders often consider ITT results as most relevant. However, the respective estimand only yields a clinically meaningful comparison of two treatment arms if subsequent therapies are already approved and reflect clinical practice. We illustrate different scenarios where subsequent therapies are not yet approved drugs and thus do not reflect clinical practice. In such situations the hypothetical strategy could be more meaningful from patient's and prescriber's perspective. The cross-industry Oncology Estimand Working Group (www.oncoestimand.org) was initiated to foster a common understanding and consistent implementation of the estimand framework in oncology clinical trials. This paper summarizes the group's recommendations for appropriate estimands in the presence of treatment switching, one of the key intercurrent events in oncology clinical trials. We also discuss how different choices of estimands may impact study design, data collection, trial conduct, analysis, and interpretation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丘比特应助虚影采纳,获得10
2秒前
头发茂密的我完成签到,获得积分10
2秒前
2秒前
2秒前
桀桀桀发布了新的文献求助10
6秒前
6秒前
赘婿应助Arui采纳,获得10
7秒前
10秒前
小羊发布了新的文献求助10
11秒前
斯文的萧关注了科研通微信公众号
12秒前
13秒前
14秒前
honeylaker完成签到,获得积分10
16秒前
111111111发布了新的文献求助10
16秒前
16秒前
云澈完成签到,获得积分10
18秒前
Arui发布了新的文献求助10
19秒前
21秒前
24秒前
呜呜完成签到 ,获得积分10
25秒前
chen发布了新的文献求助10
26秒前
29秒前
星辰大海应助miles采纳,获得10
31秒前
34秒前
五十完成签到 ,获得积分10
34秒前
一直向前发布了新的文献求助10
35秒前
35秒前
领导范儿应助斯文的萧采纳,获得10
36秒前
烟色晚空完成签到,获得积分10
36秒前
wish发布了新的文献求助10
40秒前
ding应助Steven采纳,获得10
40秒前
赵鹏飞发布了新的文献求助10
42秒前
直觉关注了科研通微信公众号
42秒前
Jing发布了新的文献求助10
48秒前
范户晓发布了新的文献求助10
50秒前
乐乐应助土豆采纳,获得10
50秒前
墨守成规发布了新的文献求助10
51秒前
51秒前
完美世界应助双椒兔丁采纳,获得10
55秒前
55秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989868
求助须知:如何正确求助?哪些是违规求助? 3531994
关于积分的说明 11255752
捐赠科研通 3270793
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882215
科研通“疑难数据库(出版商)”最低求助积分说明 809208